biospaceMarch 21, 2018
Tag: Evolva , financial results
Evolva (SIX:EVE) posted its financial resultstoday for the period from 1 January to 31 December 2017, and provided business highlights that illustrate how the Company is executing on its strategic transformation plan which was put in place last August.
Elements of this transformation have included accelerating growth of our commercial products, building stronger R&D operations, successfully streamlining our operations and fortifying our cash balance. These elements have provided Evolva with a strong base to grow our product revenues while strengthening our world-class research and development capabilities to bring important products to market quickly.
Key business highlights
Financial highlights:
Evolva CEO Simon Waddington said, "The commercial launch of EverSweet marks the fifth product platform that Evolva has advanced from concept to market. We are very proud of this track-record and look forward to advancing further products that meet important societal needs. Evolva is a world-leader in applying cutting edge biotechnology to allow for sustainable bioproduction of next-generation ingredients that positively impact the health, nutrition and protection of people and animals."
Evolva CFO Oliver Walker commented, "Our finances are developing in line with our financial plan. We have a solid cash position of almost CHF 100 million, remain debt-free, and have significantly trimmed our burn rate. By any measure, Evolva has never been in such a strong financial position."
Press/analyst call at 10AM CET on 20 March 2018
Simon Waddington (CEO) and Oliver Walker (CFO) will present the results in call for media and analysts.
The full press release text, Powerpoint presentation and annual accounts are available on Evolva’s website. A replay will be available as a podcast for 2 weeks after the call. The link to the podcast will be posted on Evolva’s website
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: